How I treat myelofibrosis after failure of JAK inhibitors.

Abstract excerpt

The introduction of JAK inhibitors, leading to regulatory approval of ruxolitinib, represents a major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in splenomegaly and improved quality of life from symptom improvement. It is a paradox, however, that, despite inhibition of signaling downstream of disease-related driver mutations, JAK inhibitor treatment is not associated with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Splenomegaly
• Share to Aged
• Share to Janus Kinase 2